Randomized trial to compare acceptability of magnesium sulphate administration for preeclampsia and eclampsia: Springfusor pump versus standard of care.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

To determine the acceptability of Springfusor® pump for the administration of Magnesium Sulphate in preeclampsia and eclampsia.

Who Took Part

The age groups tagged for this paper are young adults and adults, women only.

Eligible women had a systolic blood pressure of ≥140mmHg and or diastolic blood pressure >90mmHg, proteinuria ≥+1, and the physician's decision to start on MgSO4.

Four-hundred-ninety-six participants were randomized to a Springfusor® pump group (n = 248) or control (standard of care) (n = 248) administration of MgSO4.

How the Study Was Run

In design terms this was a randomized and open-label study.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Being open-label, the Vitamin D, K2, Magnesium and Zinc study did not mask who received what.

Randomized Open Label Clinical Trial.

The study was conducted at Kawempe National Referral Hospital.

Both arms received the rest of the care for preeclampsia/eclampsia as per the hospital guidelines.

Acceptability of the method of administration was assessed using a Likert scale (1-5; 1 and 2: acceptable and 3-5: unacceptable).

Pain at the site of MgSO4 administration was assessed using a Visual Analogue Scale 1-7, (1 minimal pain and 7 worst pain).

What Was Measured

Comparisons were assessed with the Chi-square test, Mann Whitney-Wilcoxon test, and Students' t-test.

PubMed files the paper under topics including Magnesium Sulfate, Pre-Eclampsia, Eclampsia and Standard of Care.

What This Means in Plain Language

The paper is a randomized and open-label study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 2 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (PloS one), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.